RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has received a Phase II Small Business Innovation Research (SBIR) grant in the amount of $923,080, to be disbursed over two years, to support the development of anticoagulant reversing agents, compounds PolyMedix calls heptagonists.
